Literature DB >> 15870965

Impact of taurolidine on the growth of CC531 coloncarcinoma cells in vitro and in a laparoscopic animal model in rats.

G Nestler1, H U Schulz, D Schubert, S Krüger, H Lippert, M Pross.   

Abstract

BACKGROUND: The object of this study was to examine the effect of taurolidine on intraabdominal tumor growth in a laparoscopic animal model. We tested the cytotoxic, antiadhesive, and anti-invasive effects of this substance on CC531 adenocarcinoma cells in vitro and in vivo using WAG rats.
METHODS: For in vitro experiments, Transwell dual chambers with polycarbonate filters coated with 100 microg/cm2 Matrigel were used to investigate the effects of 5, 10, and 20 microl of 2.0% taurolidine on the invasion of 1 x 10(5) CC531 adenocarcinoma cells. For the adhesion assays, tumor cells were applied onto microtiter plates coated with 5, 10, and 20 microl taurolidine and 0.9% NaCl solution for the control group subsequently. For in vivo experiments, 40 WAG rats were randomized into three therapy groups and one control group. All animals underwent laparoscopy and received 1 ml of CC531 adenocarcinoma cells (5 x 10(6) cells/ml) intraabdominally at the beginning of the procedure. According to the randomization, the rats were administered taurolidine with different concentrations or 1 ml of 0.9% NaCl solution for the control group. After 21 days, the animals were killed and the intraabdominal tumor weight was determined.
RESULTS: For the in vitro experiments, we found a moderate cytotoxicity and a significant inhibition of tumor cell adhesion and invasion (p < 0.01) by all taurolidine concentrations used in the assay. For in vivo experiments, the application of all concentrations of taurolidine significantly decreased the intraperitoneal tumor weight (p < 0.001).
CONCLUSION: Taurolidine significantly decreases adhesion and invasion of CC531 adenocarcinoma cells in vitro and significantly diminishes tumor growth in vivo. This may offer additional therapeutic options for laparoscopic surgery for colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15870965     DOI: 10.1007/s00464-003-9301-8

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  28 in total

1.  Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator.

Authors:  M A Reymond; B Hu; A Garcia; T Reck; F Köckerling; J Hess; P Morel
Journal:  Surg Endosc       Date:  2000-01       Impact factor: 4.584

2.  Image analysis of Transwell assays in the assessment of invasion by malignant cell lines.

Authors:  Lynette Connolly; Perry Maxwell
Journal:  Br J Biomed Sci       Date:  2002       Impact factor: 3.829

3.  Sustained anti-adherence activity of taurolidine (Taurolin) and noxythiolin (Noxyflex S) solutions.

Authors:  J I Blenkharn
Journal:  J Pharm Pharmacol       Date:  1988-07       Impact factor: 3.765

4.  A new in vitro assay for quantitating tumor cell invasion.

Authors:  L A Repesh
Journal:  Invasion Metastasis       Date:  1989

5.  Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent.

Authors:  P Calabresi; F A Goulette; J W Darnowski
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

6.  The effect of taurolidine on brain tumor cells.

Authors:  Ruediger Stendel; Gisela Stoltenburg-Didinger; Claudia Lotte Al Keikh; Michaela Wattrodt; Mario Brock
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

7.  [Surgical therapy of pleural empyema with tauroline].

Authors:  R Bieselt
Journal:  Langenbecks Arch Chir       Date:  1997

Review 8.  Port site metastases after laparoscopic colorectal surgery for cure of malignancy.

Authors:  S D Wexner; S M Cohen
Journal:  Br J Surg       Date:  1995-03       Impact factor: 6.939

9.  Taurolidine instillation as therapy for empyema thoracis. A prospective study of 50 patients.

Authors:  A A Conlan; E Abramor; P Delikaris; S S Hurwitz
Journal:  S Afr Med J       Date:  1983-10-15

10.  Exfoliated cells and in vitro growth in colorectal cancer.

Authors:  D Skipper; A J Cooper; J E Marston; I Taylor
Journal:  Br J Surg       Date:  1987-11       Impact factor: 6.939

View more
  8 in total

1.  In-vitro effects of taurolidine alone and in combination with mitoxantrone and/or piroxicam on canine transitional cell carcinoma.

Authors:  Brittney Byer; Lisa J Schlein; Barbara Rose; Bernard Séguin
Journal:  Can J Vet Res       Date:  2020-04       Impact factor: 1.310

2.  Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice.

Authors:  Ansgar Michael Chromik; Sebastian Huss; Hayssam Osseili; Adrien Daigeler; Sabine Kersting; Dominique Sülberg; Ulrich Mittelkötter; Thomas Herdegen; Waldemar Uhl; Annette M Müller
Journal:  J Carcinog       Date:  2010-04-16

3.  Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines.

Authors:  Denise K Walters; Roman Muff; Bettina Langsam; Philipp Gruber; Walter Born; Bruno Fuchs
Journal:  Invest New Drugs       Date:  2007-04-26       Impact factor: 3.850

4.  Taurolidine induces epithelial-mesenchymal transition via up-regulation of the transcription factor Snail in human pancreatic cancer cell lines.

Authors:  Birgit Hotz; Ulrike Erben; Marco Arndt; Heinz J Buhr; Hubert G Hotz
Journal:  Int J Colorectal Dis       Date:  2014-09-03       Impact factor: 2.571

5.  Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin.

Authors:  Ergül Eyol; Annemarie Boleij; Rachel R Taylor; Andrew L Lewis; Martin R Berger
Journal:  Clin Exp Metastasis       Date:  2008-02-08       Impact factor: 5.150

6.  Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells.

Authors:  Georg Eschenburg; Christian Luckert; Konrad Reinshagen; Robert Bergholz
Journal:  Genes Cancer       Date:  2014-11

7.  Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo.

Authors:  M Buchholz; B Majchrzak-Stiller; S Hahn; D Vangala; R W Pfirrmann; W Uhl; C Braumann; A M Chromik
Journal:  BMC Cancer       Date:  2017-03-24       Impact factor: 4.430

Review 8.  Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (review).

Authors:  Hanns Möhler; Rolf W Pfirrmann; Karl Frei
Journal:  Int J Oncol       Date:  2014-07-28       Impact factor: 5.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.